Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of Cyclosporine Ophthalmic Solution 0.010% Compared with its Vehicle Administered QID for 3 Months Followed by a 9 Month Open-Label Phase in Patients with Atopic Keratoconjunctivitis

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of Cyclosporine Ophthalmic Solution 0.010% Compared with its Vehicle Administered QID for 3 Months Followed by a 9 Month Open-Label Phase in Patients with Atopic Keratoconjunctivitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Keratoconjunctivitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan

    • Most Recent Events

    • 07 Jun 2018 According to an Allergan media release, the company has received approval from Health Canada for RESTASIS MULTIDOSE (Cyclosporine Ophthalmic Emulsion) 0.05%.
    • 22 May 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top